Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD AMENDMENT

22nd Nov 2018 07:10

FORM 8.3 Amendment to Purchases & Sales

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Barclays PLC.
(b) Owner or controller of interest and short
positions disclosed, if different from 1(a):
(c) Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD
relevant securities this form relates:
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken: 16 November 2018
(f) In addition to the company in 1(c) above, is the discloser making YES:
disclosures in respect of any other party to the offer? SHIRE PLC

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)]

Class of relevant security: Ordinary NPV
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
and/or controlled: 11,105,037 1.40% 12,379,978 1.56%
(2) Cash-settled derivatives:
11,907,286 1.50% 10,255,100 1.29%
(3) Stock-settled derivatives (including options)
and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38%
(4)
TOTAL: 33,533,923 4.22% 33,576,678 4.23%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit
security securities
ADR Purchase 15,000 18.9633 USD
ADR Purchase 33,828 18.8853 USD
ADR Purchase 35,366 18.9673 USD
ADR Purchase 36,200 19.0400 USD
ADR Purchase 40,057 18.8918 USD
ADR Purchase 53,360 18.9445 USD
ADR Sale 20 18.9700 USD
ADR Sale 20,480 19.0100 USD
ADR Sale 35,366 18.9673 USD
ADR Sale 36,200 19.0400 USD
ADR Sale 40,057 18.8918 USD
ADR Sale 50,000 19.0170 USD
ADR Sale 87,168 18.9215 USD
Ordinary NPV Purchase 100 4,305.0000 JPY
Ordinary NPV Purchase 100 4,301.0000 JPY
Ordinary NPV Purchase 500 4,301.8800 JPY
Ordinary NPV Purchase 800 4,323.0500 JPY
Ordinary NPV Purchase 900 4,310.1666 JPY
Ordinary NPV Purchase 1,200 4,319.5833 JPY
Ordinary NPV Purchase 1,300 4,357.0000 JPY
Ordinary NPV Purchase 1,900 4,303.6421 JPY
Ordinary NPV Purchase 2,000 4,315.0500 JPY
Ordinary NPV Purchase 2,300 4,306.9782 JPY
Ordinary NPV Purchase 4,500 4,307.6222 JPY
Ordinary NPV Purchase 4,600 4,323.2173 JPY
Ordinary NPV Purchase 5,100 4,316.0980 JPY
Ordinary NPV Purchase 18,100 4,309.0165 JPY
Ordinary NPV Purchase 32,000 4,306.4250 JPY
Ordinary NPV Purchase 58,100 4,293.0000 JPY
Ordinary NPV Purchase 67,800 4,350.0000 JPY
Ordinary NPV Purchase 68,200 4,315.5176 JPY
Ordinary NPV Purchase 90,000 4,314.3366 JPY
Ordinary NPV Purchase 195,000 4,298.4666 JPY
Ordinary NPV Purchase 244,000 4,319.9151 JPY
Ordinary NPV Purchase 443,800 4,314.2559 JPY
Ordinary NPV Purchase 449,900 4,315.5334 JPY
Ordinary NPV Sale 100 4,305.0000 JPY
Ordinary NPV Sale 100 4,301.0000 JPY
Ordinary NPV Sale 200 4,299.1500 JPY
Ordinary NPV Sale 500 4,301.8800 JPY
Ordinary NPV Sale 800 4,323.0500 JPY
Ordinary NPV Sale 900 4,310.1666 JPY
Ordinary NPV Sale 1,200 4,308.6666 JPY
Ordinary NPV Sale 1,700 4,297.0588 JPY
Ordinary NPV Sale 1,900 4,303.6421 JPY
Ordinary NPV Sale 2,000 4,315.0500 JPY
Ordinary NPV Sale 2,000 4,308.0000 JPY
Ordinary NPV Sale 2,200 4,342.8181 JPY
Ordinary NPV Sale 2,300 4,306.9782 JPY
Ordinary NPV Sale 2,900 4,295.1724 JPY
Ordinary NPV Sale 3,100 4,320.3548 JPY
Ordinary NPV Sale 3,800 4,314.9211 JPY
Ordinary NPV Sale 4,300 4,308.0162 JPY
Ordinary NPV Sale 4,700 4,323.0212 JPY
Ordinary NPV Sale 5,000 4,313.1800 JPY
Ordinary NPV Sale 5,100 4,316.0980 JPY
Ordinary NPV Sale 5,700 4,301.9122 JPY
Ordinary NPV Sale 7,300 4,293.3561 JPY
Ordinary NPV Sale 9,600 4,302.5520 JPY
Ordinary NPV Sale 15,200 4,329.0592 JPY
Ordinary NPV Sale 68,200 4,314.5586 JPY
Ordinary NPV Sale 403,800 4,309.8164 JPY
Ordinary NPV Sale 443,800 4,314.2559 JPY
Ordinary NPV Sale 712,700 4,314.1426 JPY

(b) Cash-settled derivative transactions

Class of Product Nature of dealing Number of Price per
relevant description reference unit
security securities
Ordinary NPV CFD Long 15,500 4,356.5643 JPY
Ordinary NPV SWAP Short 600 4,306.3333 JPY
Ordinary NPV SWAP Short 58,100 4,293.0000 JPY

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 21 Nov 2018
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

Identity of the person whose positions/dealings Barclays PLC.
are being disclosed:
Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD
relevant securities this from relates:

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class Product Writing, Number Exercise Type Expiry
of description purchasing, of price date
relevant selling, securities per unit
security varying etc to which
option
relates
Ordinary NPV Call Options Purchased 39,000 5781.0000 European 14 Dec 2018
Ordinary NPV Call Options Purchased 40,000 6182.0000 European 14 Dec 2018
Ordinary NPV Call Options Written -460,000 6182.0000 European 14 Dec 2018
Ordinary NPV Call Options Written -114,000 4750.0200 European 14 May 2019
Ordinary NPV Call Options Written -104,700 5065.8300 European 17 Apr 2019
Ordinary NPV Call Options Written -78,000 5781.0000 European 14 Dec 2018
Ordinary NPV Call Options Written -75,900 4286.5200 European 6 Sep 2019
Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019
Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018
Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019
Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019
Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018
Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019
Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019
Ordinary NPV Call Options Purchased 10,000,000 4562.0355 European 4 Dec 2018
Ordinary NPV Call Options Written -10,000,000 4562.0355 European 4 Dec 2018
Ordinary NPV Put Options Purchased -10,000,000 4562.0355 European 4 Dec 2018
Ordinary NPV Put Options Written 10,000,000 4562.0355 European 4 Dec 2018

3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005597/en/

Copyright Business Wire 2018


Related Shares:

Barclays
FTSE 100 Latest
Value8,756.72
Change-2.27